Trajectories of antidepressant and antipsychotic use | Acta Psychiatrica Scandinavica MD LinxInternal Medicine Article: Multi-trajectories of antidepressant and antipsychotic use: A 11-year naturalistic study in a community-based sample.
Trajectories of antidepressant and antipsychotic use | Acta Psychiatrica Scandinavica MD LinxPsychiatry Article: Multi-trajectories of antidepressant and antipsychotic use: A 11-year naturalistic study in a community-based sample.
Seasonal Affective Disorder (SAD) Therapeutics Market is pegged at around US$ 450 million in 2019 PharmiWeb.comThe seasonal affective disorder (SAD) therapeutics market is pegged at around US$ 450 million in 2019, with a modest Y-o-Y increase of 3.9% over 2018, ...
For those with treatment-resistant depression, ketamine offers hope Philly.comAccording to studies, 50 to 80 percent of patients with treatment-resistant depression get relief from their symptoms with ketamine infusions, and no one knows ...
Hospitalization for MDD Costly, Associated With High Readmission Rates Psychiatry AdvisorHospitalizations for major depressive disorder (MDD) were costly and associated with high risk for readmission, according to study results published in the ...
'Breakthrough for patients': FDA approves 1st postpartum depression drug WLWT CincinnatiFor the first time, the U.S. Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say ...
'Breakthrough for patients': FDA approves 1st postpartum depression drug KCCI Des MoinesFor the first time, the U.S. Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say ...
'Breakthrough for patients': FDA approves 1st postpartum depression drug WMTW PortlandFor the first time, the U.S. Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say ...
